EIF3L

Across TCGA pan-cancer cohorts, EIF3L mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EIF3L data layer compared with 26 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EIF3L mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated EIF3L expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where EIF3L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	1.000	0.637	.003	22	view →
CCRCC	OS	Tertile	All	0.680	0.931	.008	16	view →
LUAD	DFS	Tertile	III,IV	0.862	0.262	.008	13	view →
PDAC	DFS	Median	All	0.455	0.268	.009	12	view →
GBM	OS	Quartile	All	0.564	0.302	.018	4	view →
LSCC	DFS	Median	All	0.907	0.464	.009	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EIF3L–HNSC (OS)

Open the HNSC breakdown →